ConSun Pharmaceutical Group Limited has issued a proxy form summarising resolutions to be tabled at its annual general meeting scheduled for 26 May 2026 at 10:00 a.m. The meeting will be held in a hybrid format, combining a physical venue at 10/F, United Centre, 95 Queensway, Admiralty, Hong Kong, with an online platform.

Key items on the agenda are as follows:

1. FY 2025 Financial Statements • Shareholders will vote to receive and approve the audited consolidated financial statements, the directors’ report and the independent auditor’s report for the year ended 31 December 2025.

2. Board Composition and Remuneration • Re-election of executive director Mr An Meng. • Re-election of independent non-executive directors Professor Li Yikai and Mr Duan Weiwu. • Authorisation for the board to determine directors’ remuneration.

3. Shareholder Returns • Proposal to declare and pay a final dividend of HKD0.40 per ordinary share for FY 2025, subject to shareholder approval.

4. Auditor Appointment • Re-appointment of KPMG as external auditor with authority for the board to fix remuneration.

5. Capital Management Mandates • General mandate permitting the board to issue, allot and deal with additional shares not exceeding 20% of the company’s issued share capital. • General mandate permitting share repurchases up to 10% of issued share capital. • Authority to extend the share-issuance mandate by the number of shares repurchased under the buy-back mandate.

Shareholders entitled to attend and vote may appoint one or more proxies; completed proxy forms must be lodged with Computershare Hong Kong Investor Services Limited no later than 48 hours before the meeting. Proxies participating online will receive unique login credentials via email.

Approval of these resolutions will finalise FY 2025 reporting, refresh board mandates and authorise a cash dividend, underscoring ConSun Pharma’s ongoing capital return and governance framework ahead of the new financial year.